RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Repare Therapeutics Stock

Repare Therapeutics P/S 2024

Repare Therapeutics P/S

5.22

Ticker

RPTX

ISIN

US7602731025

WKN

A2P7AV

As of Aug 17, 2024, Repare Therapeutics's P/S ratio stood at 5.22, a -40.34% change from the 8.75 P/S ratio recorded in the previous year.

The Repare Therapeutics P/S history

Repare Therapeutics Aktienanalyse

What does Repare Therapeutics do?

Repare Therapeutics Inc is a biotechnology company specializing in the development of precision medicines for the treatment of cancer. It was founded in 2016 by four leading scientists and is headquartered in Montreal, Canada. The company utilizes an innovative and unique approach called CRISPR-Cas9 to identify and target genetic mutations in cancer cells. The history of Repare Therapeutics Inc stems from a collaboration among renowned cancer researchers. In 2016, the founders, who already had extensive experience in drug development, pooled their resources to create a new generation of cancer therapies. Using the innovative CRISPR-Cas9 system, they were able to specifically identify genetic alterations in cancer cells and significantly reduce tumor burden. Since its inception, the company has formed strong partnerships and successfully raised capital to continue its research and development. Repare Therapeutics has a unique business model focused on developing precision medicine for patients with specific types of cancer. The company combines CRISPR-Cas technology and machine learning to identify genetic mutations in cancer cells and correlate them with an extensive dataset of available clinical studies. This systematic approach allows for faster and more precise identification of suitable target molecules that may serve as potential therapy options for cancer. Repare Therapeutics specializes in quickly and efficiently developing molecules that target these target molecules and advancing them through clinical trials. The company distributes its precision medicines in three different sectors: oncology, therapeutics, and research. The oncology sector specializes in the development of precision medicines for the treatment of cancer. The therapeutics sector offers solutions for the medical care of patients through the development of novel therapies. The research department focuses on developing new precision medicines and advancing innovations in cancer research. Repare Therapeutics offers various products tailored to the needs of cancer patients. The CRISPR-Cas9 technology is being used to advance multiple clinical programs aimed at regulating gene expression in tumor cells and enhancing the effectiveness of cancer therapies. The company's flagship product, RP-3500, is a precision medicine specifically targeted against a gene called KRAS, which plays a crucial role in many types of cancer. The medication has demonstrated strong efficacy in clinical trials and is currently in Phase 1 studies. In summary, Repare Therapeutics Inc is an innovative biotechnology company specializing in the development of precision medicines against cancer. The use of CRISPR-Cas9 technology in combination with machine learning allows for faster identification of suitable target molecules that may serve as potential therapy options for cancer. The company offers various precision medicines that benefit cancer patients. With its numerous research programs and clinical trials, Repare Therapeutics is poised to become a leading player in cancer treatment and research. Repare Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Repare Therapeutics's P/S Ratio

Repare Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Repare Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Repare Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Repare Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Repare Therapeutics stock

What is the price-to-earnings ratio of Repare Therapeutics?

The price-earnings ratio of Repare Therapeutics is currently 5.22.

How has the price-earnings ratio of Repare Therapeutics changed compared to last year?

The price-to-earnings ratio of Repare Therapeutics has increased by -40.34% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Repare Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Repare Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Repare Therapeutics affect the company?

An increase in the price-earnings ratio of Repare Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Repare Therapeutics affect the company?

A decrease in the price-earnings ratio of Repare Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Repare Therapeutics?

Some factors that influence the price-earnings ratio of Repare Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Repare Therapeutics pay?

Over the past 12 months, Repare Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Repare Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Repare Therapeutics?

The current dividend yield of Repare Therapeutics is .

When does Repare Therapeutics pay dividends?

Repare Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Repare Therapeutics?

Repare Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Repare Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Repare Therapeutics located?

Repare Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Repare Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Repare Therapeutics from 8/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/17/2024.

When did Repare Therapeutics pay the last dividend?

The last dividend was paid out on 8/17/2024.

What was the dividend of Repare Therapeutics in the year 2023?

In the year 2023, Repare Therapeutics distributed 0 USD as dividends.

In which currency does Repare Therapeutics pay out the dividend?

The dividends of Repare Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Repare Therapeutics

Our stock analysis for Repare Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Repare Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.